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Multidrug resistance (MDR) contributes to the failure of chemotherapy and high mortality in non-small cell
lung cancer (NSCLC). We aim to identify MDR genes that predict tumor response to chemotherapy. 199
NSCLC fresh tissue samples were tested for chemosensitivity by MTT assay. cDNA microarray was done
with 5 samples with highest resistance and 6 samples with highest sensitivity. Expression of ABCC3 mRNA
and protein was detected by real-time PCR and immunohistochemisty, respectively. The association
between gene expression and overall survival (OS) was examined using Cox proportional hazard regression.
44 genes were upregulated and 168 downregulated in the chemotherapy-resistant group. ABCC3 was one of
the most up-regulated genes in the resistant group. ABCC3-positive expression correlated with lymph node
involvement, advanced TNM stage, more malignant histological type, multiple-resistance to anti-cancer
drugs, and reduced OS. ABCC3 expression may serve as a marker for MDR and predictor for poor clinical
outcome of NSCLC.

L

ung cancer is the leading cause of cancer morbidity and mortality worldwide. Non-small cell lung cancer
(NSCLC) accounts for 80–85% of lung cancer with a 5-year survival rate of 15%1. Although surgery is
regarded as the best possible treatment for NSCLC, only 20–25% of tumors are suitable for potentially
curative resection2 and despite complete surgical resection, the recurrence rate remains high (30–70%).
Adjuvant chemotherapy may reduce recurrences by eradicating the subclinical and micro-metastatic disease2.
However, the heterogeneity of NSCLC tumors and resistance to multiple drugs results in a poor response to
chemotherapy and reduced survival2. Multidrug resistance (MDR) is a multifactorial process and a major obstacle
to treatment for NSCLC patients2. Identification of biomarkers for predicting an individual’s resistance to
chemotherapy and for rationally selecting the most efficacious therapeutic agents is dependent upon understanding the molecular alterations that contribute to MDR in lung cancer.
In vitro anticancer drug sensitivity tests can identify biomarkers to predict chemosensitivity, improve chemotherapeutic response and design individualized chemotherapy3–5. Such tests as MTT (3-(4,5-Dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide), CD-DST (collagen gel droplet-embedded culture drug sensitivity test)
and HDRA (histoculture drug response assay) have been developed for a variety of malignancies. MTT chemosensitivity test might help to predict tumor response in ovarian cancer and identify the optimum adjuvant
chemotherapy for esophageal squamous cell carcinoma. HDRA might be feasible for predicting the efficacy
and selecting the proper anticancer drug for lung cancer6. CD-DST test for ‘‘new generation’’ anticancer drugs
by using surgically resected specimens of NSCLC patients may predict tumor response to postoperative chemotherapy7. We applied MTT assay using resected NSCLC tumor tissues to stratify patients into chemotherapysensitive and resistant groups. We then analyzed the gene expression profile of the resistant and sensitive group by
cDNA Microarray to identify genes associated with MDR. 212 genes with differential expression were identified
including 44 upregulated and 168 down regulated in the chemotherapy-resistant group compared to the sensitive
group. ABCC3 was one of the most up-regulated genes in the resistant group.
ABCC3 is a member of the ATP-binding cassette (ABC) transporters family. ABC transporters are highly
expressed in tumor cells where they actively efflux a broad spectrum of anticancer drugs and thus contribute
to MDR8–11. ABCC3 is a member of the multidrug resistance-associated protein (MRP) subfamily which is
involved in MDR. ABCC3 expression has been shown to be higher in NSCLC than that in SCLC12 and
ABCC3 expression correlated with decreased sensitivity of lung cancer cells to anticancer drugs (vincristine,
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etoposide, and cisplatin)13, and especially to methotrexate and doxorubicin in NSCLC14,15. ABCC3 is also overexpressed in Anip973/
NVB cells consistent with involvement of ABCC3 in NVB-resistance
in lung cancer16. However, the mechanism underlying the role of
ABCC3 in MDR to taxanes (paclitaxel and docetaxel), gemcitabine,
and cisplatin in NSCLC remains largely unknown. To assess whether
ABCC3 expression has predictive value in chemosensitivity and prognosis in NSCLC, we examined the expression of ABCC3 in patients
with resected NSCLC tumors and evaluated its association with
tumor characteristics and sensitivity to chemotherapy. Our goal
was to examine the specific genetic traits of tumors as a means of
predicting their chemosensitivity to ‘‘new generation’’ anticancer
drugs. The results, if confirmed, would possibly identify biomarkers
useful to predict clinical outcome of NSCLC.

Results
MTT assay. MTT assay was successfully performed using primary
cancer cells from tissues of 199 patients; 69 were highly sensitive to all
the 5 drugs and were categorized as the highly sensitive group; 44
were resistant to all the 5 drugs and were categorized as resistant
group; and 86 were partially sensitive to anticancer drugs and
categorized as the moderate-sensitive group. Samples for 11
patients (6 patients with highest sensitivity and 5 patients with the
highest resistance to all the 5 drugs) were selected for gene expression
microarray. Resistance index of the 11 patients is shown in
Supplemental Table 1.
Gene expression microarray. To identify potential predictors for
chemosensitivity, cDNA microarray was used to analyze the gene
expression profiling of the resistant and sensitive group. Fold change
measurements were analyzed by SAM. The transcripts with fold
change .2 (upregulated) or ,1/2 (downregulated) and jScore(d)j
$ 2 were considered to have significantly differential expression
between the two groups. The differentially expressed elements
were identified by the two-sided statistical tolerance interval (95%)
with a cut-off of false discovery rate at 10%. Two hundred-twelve

Figure 1 | Heat map generated by hierarchical clustering of differentially
expressed genes between the 5 resistant and 6 sensitive samples (Rows:
tumor samples; Columns: genes). Differentially expressed genes (Red:
upregulated; Green: downregulated) were selected at false discovery rate of
10%.
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(212) genes were differentially expressed between the resistant and
sensitive group. Compared to sensitive group, 44 were upregulated
and 168 downregulated in chemotherapy-resistant group. Those
genes spanned distinct functional families involved in biological
processes including cell apoptosis, cell cycle, cell adhesion, signal
transduction and ABC transporter (Supplemental Table 2 and 3).
Hierarchical clustering was performed on the 11 arrays based on the
differentially expressed genes (Fig. 1).
ABCC3 expression by real time-PCR in NSCLC. The upregulated
genes with potential predictive value for chemosensitivity in NSCLC
were evaluated by real time-PCR (date was not shown). ABCC3 was
one of the most differentially expressed in the resistant group. We
performed quantitative RT-PCR for ABCC3 in the 199 NSCLS
tumor tissues. ABCC3 mRNA level was higher in the resistant
group compared to the sensitive group (mean 6 SD: 0.4587 6
0.1324 vs. 0.1324 6 0.0866, P 5 0.001) (Fig. 2).
ABCC3 expression by IHC in NSCLC and its correlation with
clinicopathological characteristics ABCC3 immunoreactivity was
present in the cell membrane and cytoplasm of NSCLC tumor
(Fig. 3). ABCC3-positive expression was observed in 63 cases including 23 with squamous cell carcinoma (SCC), 38 with adenocarcinoma (ADC), and 2 with other types (Table 1). ABCC3 expression
correlated with pN status (P , 0.001), pathological TNM stage (P ,
0.001) and histological type (P 5 0.04).
Prognostic significance of ABCC3 expression. ABCC3-positive
expression correlated with shorter OS of NSCLC patients (P logrank , 0.001) (Fig. 4). In univariate analysis, positive pN status,
advanced TNM stage, and ABCC3-positive expression correlated
with poor prognosis (P , 0.001). In multivariate regression model,
ABCC3 expression remained a significant prognostic factor independent of pN status, pTNM stage and histological type (P ,
0.001) (Table 2).
Expression of ABCC3 and in vitro drug sensitivity. Among the 199
samples, 69 (34.6%) were sensitive, 44 (22.1%) were resistant, and 86
(44.2%) were partially sensitive to the 5 anticancer drugs. 15 (21.7%),

Figure 2 | ABCC3 expression by real time-PCR in NSCLC. ABCC3
mRNA expression was higher in the resistant group compared to the
sensitive group (P , 0.001).
2
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Figure 3 | ABCC3 protein expression in NSCLC. Positive (panel A–B) and negative (panel C–D) expressions of ABCC3 in patients were observed. (A, C,
3100, SP; B, D, 3200, SP).

20 (23.2%) and 26 (59.1%) samples of the sensitive, partial sensitive
and resistant group, respectively, were ABCC3 positive. A significant
association was observed between ABCC3-positive expression and
reduced sensitivity to the 5 anticancer drugs using the MTT assay (P
, 0.001), suggesting that ABCC3-positive expression is predictive of
chemoresistance to the 5 anticancer drugs (Supplemental Table 4).

Discussion
In this study, we performed in vitro chemosensitivity tests using
‘‘new generation’’ anticancer drugs for 199 NSCLC patients. We

observed 212 genes were significantly altered in the resistant group
compared to the sensitive group. These genes are involved in various
biological processes such as cell apoptosis, cell cycle, cell adhesion,
signal transduction and ABC transporter, which have been shown to
predict chemosensitivity in NSCLC. The resistant group with
ABCC3-positive expression had poor OS.
Multiple transporters constitute the major mechanisms of
MDR8–11. ABC transporters confer resistance to many anticancer
agents. We identified ABCC3 which has been associated with the
prognosis of different type of tumors, as one of the most upregulated

Table 1 | Association between ABCC3 expressions and clinicopathologic factors in patients with NSCLC
ABCC3 Expression
Variable
All cases
Age (years)
,60
$60
Gender
male
female
pT status
pT1
pT2
pT3
pN stage
pN0
pN1
pN2
pTNM stage
I
II
III
Histological classification
Squamous cell carcinoma
Adenocarcinoma
others

No. of Patients

(2)

(1)

(11)

(111)

Positive Rate (%)

P (x2)

199

136

28

23

12

31.66

102
97

69
67

12
16

15
8

6
6

32.36
30.93

0.456

106
93

74
62

17
11

9
14

6
6

30.19
33.33

0.459

78
108
13

57
72
7

11
16
1

6
15
2

4
5
3

26.92
33.33
46.15

0.146

76
81
42

61
51
24

11
16
1

1
10
12

3
4
5

19.74
37.04
42.86

,0.001"

72
76
51

58
50
28

10
17
1

1
8
14

3
1
8

19.45
34.21
45.10

,0.001"

91
96
12

68
58
10

5
21
2

12
11
0

6
6
0

25.27
39.59
16.67

0.04"

P value was from Fisher’s Exact test.

"
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Figure 4 | Kaplan–Meier analysis of OS in 199 NSCLC patients according
to expression of ABCC3. The patients with ABCC3-positive expression
had reduced OS.

genes in the chemoresistant group. In pancreatic cancer ABCC3
mRNA has been shown to be upregulated and associated with tumor
grading17. ABCC3 overexpression in glioblastoma multiforme
(GBM) also correlates with a higher risk of death and may be a
potential therapeutic target for GBM18. In breast cancer amplification
of ABCC3 occurs in primary breast tumors, predominantly in HER2amplified and luminal tumors19. In our study, 31.6% of the NSCLC
samples expressed ABCC3 and its expression correlated with
advanced pN status and pathological TNM stage and the patients
with ABCC3-positive expression had 2.63 times higher risk for death.
ABCC3 was highly expressed in tumor cells but not in type II
alveolar pneumocytes20. Moreover, the number of ABCC3-positive
cells was significantly increased compared to the precursor lesion of
lung adenocarcinoma (atypical adenomatous hyperplasia, AAH) to
localized non-mucinous bronchioloalveolar carcinoma (LNMBAC).
Together, these data suggest that ABCC3 is a candidate novel tumor
marker for histological diagnosis and functions as a driving factor in
carcinogenesis. We found ABCC3 expression was higher in ADC
than SCC. Recent studies have shown that gene expression patterns
of lung ADC differ substantially from SCC, and each has different
etiology, carcinogenesis, and clinicopathological behavior21,22. These
observations suggest that high expression of ABCC3 may confer a

more malignant phenotype in lung ADC patients. ABCC3 overexpression has been implicated in acquired MDR in cancer cell lines.
ABCC3 also contributes to resistance to doxorubicin in breast cancer23, to 5-fluorouracil in pancreatic cancer cells24 and resistance to
adriamycin in hepatocellular carcinoma cells, which however, can be
effectively reversed by tetramethylpyrazine25. Our results are consistentwith ABCC3 expression being predictive of resistance to paclitaxel, docetaxel, gemcitabine, vinorelbine and cisplatin in NSCLC.
The limitation in our study includes the fact that the results of
MTT were not compared with the optimal regimen. The current
study did not include the functional study of drug-resistant related
genes that have been screened, thus further studies are needed to
explore the detailed process of multiple-drug resistance and to provide more evidence of how ABCC3 is involved in MDR in vitro.
Although we collected samples from large amounts of NSCLC
patients, only 11 samples were eventually selected for gene expression microarray, which also limited the extent of application. Our
observations need to be validated in a multiple-centered study involving patients with a large sample size. However, our observations
support the notion that chemotherapy combined with targeted therapy may improve the efficacy in patient with MDR tumors.
Most previous studies have screened drug-resistant genes from cell
lines in vitro, while our study validated and predicted drug resistance
by using primary cells of human cancer tissues. We conducted drug
resistance experiments, identified drug-resistant genes directly from
clinical specimens of NSCLC patients, and validated the observations
in vivo, which accurately reflected the original drug sensitivity vs.
resistance in patients. We have employed a new method to popularize the MDR genes screening, which has clinical implications for
individualized therapy for a variety of tumors.
In summary, MTT drug response assay in surgically resected
NSCLC may have clinical utility for predicting tumor response to
chemotherapy and to prospectively identify drug sensitive and resistant subpopulations. ABCC3-positive expression correlated with
enhanced chemoresistance and reduced OS in NSCLC patients.
For patients with resectable stage IB to IIIA NSCLC, cisplatin-based
regimen (in combination with Paclitaxel, Docetaxel, Gemcitabine,
Vinorelbine, etc.) is the majorchoice for postoperative adjuvant therapy. However, some patients develop multiple-drug resistance,
which leads to failures in therapy and a poor prognosis. By using
in vitro MTT assay, we could evaluate an individual patient’s sensitivity vs. resistance to conventional anticancer drugs before the
treatment is employed. Based on the results, an unnecessary cytotoxicity/side effects caused by an insensitive drug could be avoided.
In our study, we found the correlation of ABCC3 expression with

Table 2 | Prognostic factors for NSCLC patients
Variables
Age (year)
,60 vs. $60
Gender
Male vs. female
pT status
pT2-4 vs. pT1
pN stage
pN1-2 vs. pN0
pTNM stage
II-III vs. I
Histological classification
Adenocarcinoma vs. Squamous cell
cancer
ABCC3 expression
ABCC 3(1) vs. ABCC 3(2)

HR

Univariate 95% CI

1.034

0.584–1.830

1.291

P

HR1

Multivariate 95% CI

P1

0.909

-1

-

-

0.733–2.275

0.377

-

-

-

1.009

0.621–1.639

0.971

-

-

-

2.388

1.640–3.477

,0.001

-

-

-

2.461

1.691–3.583

,0.001

-

-

-

0.653

0.403–1.058

0.083

-

-

-

2.686

2.077–3.472

,0.001

2.635

1.992–3.486

,0.001

HR, 95% CI and P values were from multivariate Cox proportional hazard regression model including all the demographic and clinical factors.
The variable with a P 1 value of . 0.05 in the multivariate model was not shown.

1
1
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multiple-drug resistance and reduced overall survival, confirming
that in vitro MTT assay is reliable and feasible in NSCLC.
Therefore, we propose ABCC3 as a novel marker to predict tumor
response to chemotherapy and postoperative clinical outcome of
NSCLC patients, which will be helpful to stratify patient subpopulation for an efficient therapy and realize the concept of personalized
medicine. Future studies will investigate whether the inhibition of
ABCC3 increases the sensitivity to chemotherapeutic agents and
provides new effective targeted therapy of NSCLC.

Methods
Patients and tissue specimens. Each patient had signed informed consent for
medical record review and tissue sample donation before surgery. This study was
approved by the institutional review board at Harbin Medical University and
conducted according to all current ethical guidelines. Fresh tumor tissues from 205
patients with NSCLC were obtained at the Department of Thoracic Surgery of the
Affiliated Tumor Hospital of Harbin Medical University between May 2008 and
August 2009. The patients were follow-up until June, 2012.
Histopathologic subtypes were determined according to the WHO classification.
The International Staging System was used for pathological staging. All tumors were
staged according to the pathological tumor/node/metastasis (pTNM) classification of
the American Joint Committee on Cancer (7th edition). All tumors were histologically reviewed by pathologists. Tumor tissue collected at the time of curative surgical
resection was placed immediately into normal saline. Then a pathologist conducted a
representative tumor biopsy and stored the tissue in RPMI-1640 for primary culture
of NSCLC cells and subsequent MTT assay within 30 minutes. Long-term storage of
the tissues was at 280uC. At the time of surgery and tissue collection, none of the
patients had received neoadjuvant chemotherapy or radiation therapy.
Primary culture of NSCLC cells. Each fresh specimen was homogenized and
digested in 0.25% trypsin. The dispersed cancer cells were filtered through an 80 mm
nylon mesh, washed twice in 500 mL RNase free PBS, centrifuged at 1000 rpm for
5 min, and then incubated in RPMI 1640 medium supplemented with 10% fetal
bovine serum and 1% (v/w) penicillin/streptomycin at 37uC in a humidified
atmosphere of 5% CO2. The samples of 6 patients were contaminated and excluded
from the consequent experiments. In total, the culture of primary cells was successful
in 199 samples.
MTT drug response assay. The NSCLC cells from each patient were seeded at a
density of 1 3 105 per well in 96-wellplates with 190 mL culture medium for 24 h.
Then the cells were treated with 10 mL gradient concentrations (103, 53, 2.53,
1.253, 0.6253, 0.3123, 0.156 3 ppc) of each of the drugs paclitaxel, docetaxel,
gemcitabine, vinorelbine and cisplatin for 72 h. ‘‘ppc’’ represents peak plasma
concentration (the highest level of drug that occurs in the plasma portion of blood
after administration of the drug). The tumor cells treated with PBS served as controls.
Then 20 mL tetrazolium salts (MTT, Sigma, 5 mg/mL) were added to each well and
incubated for 4 h. The salts were cleaved into a colored formazan product by
metabolically active cells and 100 mL DMSO was added.
After checking for complete solubilization of the purple formazan crystals, the
optical density (OD) was measured at 490 nm wavelength. The inhibition rate (IR)
was calculated as the formula: IR 5 (ODcontrol group 2 ODexperimental group)/
ODcontrol group 3 100%26–28. IR $ 50% was defined as highly sensitive; IR 30% , 50%
as moderately sensitive; and IR # 30% as resistant. The data were presented as mean
6 standard deviation (SD) from four replicate wells per microtiter plate. The samples
with the highest sensitivity or resistance to all the 5 drugs were selected for gene
expression microarray.
Gene expression microarray. Extraction and purification of total RNA was
performed using TRIZOL reagent (Invitrogen, Carlsbad, CA). RNA purity and
integrity was controlled by BioAnalyser 2100 (Agilent technologies, CA, USA). Gene
expression profiling was performed using Human Genome U133 Plus2.0 Affymetrix
(Santa Clara, USA), which included 47,400 transcripts and represented 38,500 human
genes. Target preparation for Affymetrix GenechipsTM was performed according
tothe manufacturer’s instruction. 4 mg of total RNA was reverse-transcribed and
amplified by using the RNA amplification kit (Ambion, TX, USA). Hybridization,
washing, staining and scanning of chips were carried out according to standard
protocols (Affymetrix, Santa Clara, CA). The mean 6 SD of replicated spots was
calculated for each geneby using the Acuity 4.0 software (Molecular Devices, LLC,
USA).
Microarray validation. Real time-PCR. The mRNA level of each gene was measured
by real-time-PCR using TaqMan method and quantified using an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster City, USA). GAPDH was
used as the internal control. All experiments were performed in triplicate. Relative
mRNA abundance was calculated as 22DCt [DCt 5 Ct (ABCC3) 2 Ct(GAPDH)].
Immunohistochemistry (IHC). IHC assay was performed using the labeled streptavidin-biotin (LSAB) method. In brief, tissue sections (4 mm) were cut from the tissue
blocks. To retrieve antigenicity, tissue slides were immersed in 1 mM EDTA (pH 8.0)
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and bathed in a steamer at 100uC for 15 min. To block the endogenous peroxidase
activity, the slides were incubated in methanol containing 0.3% H2O2 for 15 min. The
slides were washed with PBS and incubated with a specific mouse monoclonal
primary antibody for human ABCC3 (15800 dilution, Abcam, Cambridge, UK) at
4uC overnight. After washing with PBS, the slides were incubated with streptavidinbiotinylated anti-mouse IgG (Dako, Carpinteria, CA, USA) as the secondary antibody
for 10 min at room temperature. The slides were washed with PBS for 3 times and
stained using diaminoben-zidine tetrahydrochloride (DAB), counterstained using
hematoxylin, dehydratedand placed on coverslips. The negative controls were performed by omitting the primary antibody and replaced with PBS. Adenocarcinoma of
intestine was used as a positive control, which was provided with kit and confirmed to
express this protein. The positive staining was observed in the membrane of a cell.
Scoring. The staining results were interpreted independently and blindly by two
pathologists. For each slide, three to five randomly selected fields were evaluated. For
each field, the percentage of DAB-positive-tumor cells was calculated as: [(number of
DAB-positive tumor cells/total number of tumor cells) 3 100]. The relative staining
intensity was defined as negative for ,5%; weak (1) for 5–25%; moderate (11) for
25–50%, and strong (111) for .50% of the tumor cells stained positive for ABCC3.
Statistical analysis. The association between ABCC3 expression and tumor
characteristics (tumor size, lymph node, pathological TNM stage, histological
classification) or sensitivity to chemotherapy was evaluated by x2 test and Cox
regression. Kaplan-Meier plot was used to estimate median survival time (MST).
Overall survival (OS) time was calculated from the date of diagnosis to the date of
death or last follow-up. The association between ABCC3 expression and survival time
was analyzed by log-rank test. The effect of ABCC3 expression on OS was estimated
using hazard ratio (HR) and 95% CI was estimated using Cox proportional hazard
regression model, with adjustment for other clinical factors. A P-value ,0.05 was
considered statistically significant. All analyses were performed using SPSS 18.0
(SPSS Inc., Chicago, IL).
1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J clin 60,
277–300, 20073 (2010).
2. Group, N. M.-A. C. et al. Adjuvant chemotherapy, with or without postoperative
radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of
individual patient data. Lancet 375, 1267–1277 (2010).
3. Bertelsen, C. A., Sondak, V. K., Mann, B. D., Korn, E. L. & Kern, D. H.
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258
clinical correlations. Cancer 53, 1240–1245 (1984).
4. Shaw, G. L. et al. Correlation of in vitro drug sensitivity testing results with
response to chemotherapy and survival: comparison of non-small cell lung cancer
and small cell lung cancer. J Cell Biochem Suppl. 24, 173–185 (1996).
5. Kobayashi, H. Collagen gel droplet culture method to examine in vitro
chemosensitivity. Methods Mol Med. 110, 59–67 (2005).
6. Yoshimasu, T. et al. Data acquisition for the histoculture drug response assay in
lung cancer. The J Thorac Cardiovasc Surg. 133, 303–308 (2007).
7. Higashiyama, M. et al. Prediction of chemotherapeutic effect on postoperative
recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung
cancer patients. Lung cancer 68, 472–477 (2010).
8. Deeley, R. G., Westlake, C. & Cole, S. P. Transmembrane transport of endo- and
xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.
Physiological Rev 86, 849–899 (2006).
9. Kruh, G. D., Belinsky, M. G., Gallo, J. M. & Lee, K. Physiological and
pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent
studies on gene-disrupted mice. Cancer metastasis Rev 26, 5–14 (2007).
10. Marquez, B. & Van Bambeke, F. ABC multidrug transporters: target for
modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug
Targets 12, 600–620 (2011).
11. Borst, P., Zelcer, N. & van de Wetering, K. MRP2 and 3 in health and disease.
Cancer Lett 234, 51–61 (2006).
12. Young, L. C. et al. Expression of multidrug resistance protein-related genes in lung
cancer: correlation with drug response. Clin Cancer Res. 5, 673–680 (1999).
13. Young, L. C., Campling, B. G., Cole, S. P., Deeley, R. G. & Gerlach, J. H. Multidrug
resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein
levels with drug response and messenger RNA levels. Clin Cancer Res. 7,
1798–1804 (2001).
14. Kool, M. et al. MRP3, an organic anion transporter able to transport anti-cancer
drugs. Proc Natl Acad Sci U S A 96, 6914–6919 (1999).
15. Lockhart, A. C., Tirona, R. G. & Kim, R. B. Pharmacogenetics of ATP-binding
cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2, 685–698
(2003).
16. Hong, X. et al. Multidrug resistance-associated protein 3 and Bcl-2 contribute to
multidrug resistance by vinorelbine in lung adenocarcinoma. Int J Mol Med. 28,
953–960 (2011).
17. Konig, J. et al. Expression and localization of human multidrug resistance protein
(ABCC) family members in pancreatic carcinoma. Int J Cancer. 115, 359–367
(2005).
18. Kuan, C. T. et al. MRP3: a molecular target for human glioblastoma multiforme
immunotherapy. BMC cancer 10, 468 (2010).

5

www.nature.com/scientificreports
19. O’Brien, C. et al. Functional genomics identifies ABCC3 as a mediator of taxane
resistance in HER2-amplified breast cancer. Cancer Res. 68, 5380–5389 (2008).
20. Hanada, S. et al. Expression profile of early lung adenocarcinoma: identification of
MRP3 as a molecular marker for early progression. J Pathol. 216, 75–82 (2008).
21. Daraselia, N. et al. Molecular signature and pathway analysis of human primary
squamous and adenocarcinoma lung cancers. Am J Cancer Res. 2, 93–103 (2012).
22. Petty, R. D., Nicolson, M. C., Kerr, K. M., Collie-Duguid, E. & Murray, G. I. Gene
expression profiling in non-small cell lung cancer: from molecular mechanisms to
clinical application. Clin Cancer Res. 10, 3237–3248 (2004).
23. Liu, Y., Peng, H. & Zhang, J. T. Expression profiling of ABC transporters in a drugresistant breast cancer cell line using AmpArray. Mol Pharmacol. 68, 430–438
(2005).
24. Hagmann, W., Jesnowski, R., Faissner, R., Guo, C. & Lohr, J. M. ATP-binding
cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in
5-fluorouracil-resistant cells. Pancreatology. 9, 136–144 (2009).
25. Wang, X. B. et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and
MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep.
23, 211–215 (2010).
26. Keiko Yagi, K. K., Kunio li & Seiki Tashiro. Relationship of P-Glycoprotein and
p53 Protein to Chemosensitivity in Colorectal Cancer. Int J Clin Oncol. 2, 81–91
(1997).
27. Chen, Z., Liu, G., Chen, M., Xu, B., Peng, Y., Chen, M. & Wu, M. Screen anticancer
drug in vitro using resonance light scattering technique. Talanta. 77, 1365–1369
(2009).
28. Kuang, Y. H., Chen, X., Su, J., Wu, L. S., Liao, L. Q., Li, D., Chen, Z. S. & Kanekura,
T. RNA interference targeting the CD147 induces apoptosis of multi drug
resistantcancer cells related to XIAP depletion. Cancer Lett. 276, 189–95 (2009).

SCIENTIFIC REPORTS | 3 : 3120 | DOI: 10.1038/srep03120

Acknowledgements
This work is supported by National Natural Science of China grants (30772540 and
8177224 to LC, 81301991 to YZ) and Science and Technology of Heilongjiang Province
2grant (GC07C349, to LC).

Author contributions
L.C. and X.D. conceived and directed the project. Y.Z. and H.L. designed experiments. Y.Z.,
H.L., A.Y., Y.Y., Q.M., L.S., C.L., and H.P. carried out experiments, conducted data analysis
and interpreted the results. Y.Z., H.L., L.C., and X.D. wrote and edited the paper. All authors
reviewed the manuscript.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Zhao, Y. et al. ABCC3 as a marker for multidrug resistance in
non-small cell lung cancer. Sci. Rep. 3, 3120; DOI:10.1038/srep03120 (2013).
This work is licensed under a Creative Commons AttributionNonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0

6

